Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Layton

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Clinical Pharmacology|July 28, 2004
Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton, Lynda V Wilton, Saad A W Shakir
Drug Safety|October 12, 2017
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in EnglandVicki Osborne, Miranda Davies, Deborah Layton, et al.
Drug Safety|May 15, 2004
Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiologyDavid W J Clark, Deborah Layton, Saad A W Shakir
Drug Safety|February 18, 2010
Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk managementVicki Osborne, Lorna Hazell, Deborah Layton, et al.
Epilepsia|February 6, 2010
Safety profile of oxcarbazepine: results from a prescription-event monitoring studyYvonne Buggy, Deborah Layton, Carole Fogg, et al.
Rheumatology (Oxford, England)|July 18, 2003
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) dataDeborah Layton, Kerry Hughes, Scott Harris, et al.
Drug Safety|November 15, 2011
Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring dataDeborah Layton, Vicki Osborne, Anna Gilchrist, et al.
Cancers|January 8, 2025
Cancer-Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK Yellow Card Adverse Drug Reaction (ADR) ReportingStefanie Ho Yi Chan, Deborah Layton, Sherael Webley, et al.
Drug Safety|August 19, 2016
Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in EnglandDeborah Layton, Abigail L Coughtrie, Naseer Qayum, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton, Jane Riley, Lynda V Wilton, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Clinical Pharmacology|July 28, 2004
Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton, Lynda V Wilton, Saad A W Shakir
Drug Safety|October 12, 2017
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in EnglandVicki Osborne, Miranda Davies, Deborah Layton, et al.
Drug Safety|May 15, 2004
Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiologyDavid W J Clark, Deborah Layton, Saad A W Shakir
Drug Safety|February 18, 2010
Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk managementVicki Osborne, Lorna Hazell, Deborah Layton, et al.
Epilepsia|February 6, 2010
Safety profile of oxcarbazepine: results from a prescription-event monitoring studyYvonne Buggy, Deborah Layton, Carole Fogg, et al.
Rheumatology (Oxford, England)|July 18, 2003
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) dataDeborah Layton, Kerry Hughes, Scott Harris, et al.
Drug Safety|November 15, 2011
Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring dataDeborah Layton, Vicki Osborne, Anna Gilchrist, et al.
Cancers|January 8, 2025
Cancer-Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK Yellow Card Adverse Drug Reaction (ADR) ReportingStefanie Ho Yi Chan, Deborah Layton, Sherael Webley, et al.
Drug Safety|August 19, 2016
Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in EnglandDeborah Layton, Abigail L Coughtrie, Naseer Qayum, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton, Jane Riley, Lynda V Wilton, et al.
Pageof 6